Physician profile
Robert Warwar
NPI 1518909548
$1,196.32
in general payments reported to CMS, 2019-2025
15 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.40 · 2020: $123 · 2021: $75.92 · 2022: $366 · 2023: $223 · 2024: $22.18 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192.82 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.41 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.61 | 2022 | |
| Edwards Lifesciences Corporation | $119.56 | 2022-2023 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $116.32 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $105.66 | 2025 | Penmenvy |
| Merck Sharp & Dohme LLC | $100.30 | 2025 | Enflonsia |
| Tris Pharma INC | $80.09 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Medtronic, INC. | $57.69 | 2023 | Hawkone |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.44 | 2025 | Caplyta |
| Dexcom, INC. | $24.70 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $24.30 | 2021 | |
| Exact Sciences Corporation | $22.18 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $14.86 | 2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Warwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.